Bioreactor Segment has the Largest Share of Technology in the North America Cell Therapy Bioprocessing Market during 2021–2028

According to a new market research study on “North America Cell Therapy Bioprocessing Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Technology, Cell Type, Indication, and End User” is expected to reach US$ 13,701.0 million by 2028 from US$ 5,591.9 million in 2021. The market is estimated to grow at a CAGR of 13.7% from 2021 to 2028. The report provides trends prevailing in the North America Cell therapy bioprocessing market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increasing investments for cell and gene therapy manufacturing, and growing approvals for cell therapies are the key factors driving the market growth. However, the market is expected experiencing slow growth during the forecast period owing to the challenges such as high cost of product, regulatory challenges, and logistics challenges.

The global distribution of COVID-19 interfered with established clinical trials for a variety of reasons, as summarized in a recent Nature News article. Simultaneously, the pandemic has enabled massive private and public mobilization to promote new diagnostics, prophylactic vaccinations, and treatments. Cell and gene therapy manufacturers were involved in every aspect of this mobilization. According to clinicaltrials.gov, approximately 70 ongoing studies of cell and gene therapies to prevent or treat COVID-19 began on May 12, 2020. Products for cell therapy with anti-inflammatory pathways that appear to be well suited to COVID-19 therapy are also being investigated. Cell and gene therapy production may necessitate the use of a variety of human and animal biological materials. The risk that products derived from human plasma and blood will contaminate must be explained, but voluntary screening and testing of donors and donor materials used for SARS-CoV-2 can be a prudent measure. Manufacturing phase (open vs. closed): For early studies, those products are still produced in less closely or openly closed platforms, using an environmental protection biologic safeguard cabinet that is frequently located in a non-cGMP setting, despite an ongoing trend toward moving from the use of open production platforms to closed systems. This lower control level increases the risk of SARS-CoV-2 operators contaminating products. All such aspects will add to the future demand for the North America region's cell therapy bioprocessing market.

The market for cell therapy bioprocessing market is segmented into technology, cell type, indication, and end user. Based on technology, in 2020, the bioreactor segment accounted for the cell therapy bioprocessing market's most significant market share. The segment's growth is expected due to its utilization for making cells and scaling up the volume for cellular products. Bioreactors are the primary equipment required during the cell therapy bioprocessing thus are expected to continue their dominancy during the forecast period. However, the genome-editing technology segment is expected to grow at the fastest CAGR. Genome editing technology is widely used for targeting and designing the cellular and genes for cell therapies.

Fresenius Kabi Ag., Asahi Kasei Corporation, Sartorius Ag, Merck Kgaa, Thermo Fisher Scientific Inc., Corning Incorporated, Cytiva (Ge Healthcare), Lonza, Repligen, and Catalent Inc are among the leading companies in the North America cell therapy bioprocessing market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in January 2021, Sartorius Partners with RoosterBio. The partnership seeks to drive the scale-up of hMSC production for regenerative medicine by exploiting both companies' best-in-class solutions to dramatically minimise process development efforts, industrialise the supply chain, and accelerate the growth and commercialization of game-changing cell-based regenerative cures. 

The market for cell therapy bioprocessing market is segmented into technology, cell type, indication, and end user. Based on technology, the Cell therapy bioprocessing market is segmented into bioreactor, lyophilization, electrospinning, control flow centrifugation, ultrasonic lysis, genome editing technology, cell immortalization technology, and viral vector technology. Based on cell type, the cell therapy bioprocessing market is segmented into stem cell, immune cell, human embryonic stem cell, pluripotent stem cell, and hematopoietic stem cells. Based on indication, the cell therapy bioprocessing market is segmented into cardiovascular disease (cvd), oncology, wound healing, orthopaedic, and others. Based on end user, the cell therapy bioprocessing market is segmented into hospitals and clinics, diagnostic centres, regenerative medicine centres, and academic and research institute. Geographically, the cell therapy bioprocessing market is segmented into North America (US, Canada, Mexico).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com